CoChat

[Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]

Open access
Yamamoto, Mariko, Ide, Naohito, Kitajima, Shinzo, Obayashi, Masakazu, Asada, Kei, Matsushima, Satoru, Ito, Masaharu · 2019 · YAKUGAKU ZASSHI

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Empagliflozin reduces blood glucose levels independently of insulin secretion by reducing glucose reabsorption in the proximal renal tubules through inhibition of sodium-glucose cotransporter 2 (SGLT2). Because SGLT2 inhibitors have a different mechanism of action to conventional antidiabetic drugs, recommendations have been issued about the management of specific side effect such as ketoacidosis, urinary tract infection, and genital infection. There have been some reports of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis (euDKA), but there have been few reports about euDKA in patients with type 2 diabetes using SGLT2 inhibitors while on a low-carbohydrate diet. Here we report a patient who developed euDKA after starting a very low-carbohydrate diet while taking empagliflozin. A 51-year-old man was hospitalized with nausea and vomiting, and investigations revealed metabolic acidosis. euDKA was diagnosed from the information about medications in his drug notebook and a history of eating a low-carbohydrate diet (1900 kcal, consisting of 5.7% carbohydrate, 21.1% protein, 47.3% fat and 25.9% alcohol) for 4 d. The patient improved after infusion of acetated Ringer's solution with 5% glucose and administration of regular insulin. It is necessary for physicians and pharmacists to thoroughly inform patients about the side effects of SGLT2 inhibitors such as ketoacidosis, urinary tract infection, and genital infection. Patients should also be advised about the higher risk of euDKA associated with a low-carbohydrate diet while taking SGLT2 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1248/yakushi.19-00120

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 7

Metadata

Authors
Yamamoto, M., Ide, N., Kitajima, S., Obayashi, M., Asada, K., Matsushima, S., & Ito, M.
Affiliations
Chutoen General Medical Center (JP)
Venue
YAKUGAKU ZASSHI
Published
2019-11-01
Volume
139
Issue
11
Pages
1479-1483
ISSN
  • 0031-6903 (ISSN-L)
  • 1347-5231
OpenAlex
W2986313496
Cited by
7
References
15
Citations by year
2025: 1 · 2022: 2 · 2020: 4
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • YAKUGAKU ZASSHI (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Physiology (medical) › Diet and metabolism studies
Keywords
euglycemic diabetic ketoacidosis, empagliflozin, SGLT2 inhibitors, low-carbohydrate diet, type 2 diabetes, drug-induced ketoacidosis, metabolic acidosis, insulin therapy, patient education
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Glucose, Glucosides, Humans, Insulin, Isotonic Solutions, Male, Middle Aged, Risk, Diabetic Ketoacidosis, Treatment Outcome, Diet, Carbohydrate-Restricted

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: [Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]. https://app.cochat.ai/papers/10.1248/yakushi.19-00120
The paper
Yamamoto, M., Ide, N., Kitajima, S., Obayashi, M., Asada, K., Matsushima, S., & Ito, M. (2019). [Risk of euglycemic diabetic ketoacidosis due to low-carbohydrate diet while taking empagliflozin: a case report]. YAKUGAKU ZASSHI. https://doi.org/10.1248/yakushi.19-00120

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.